Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 15/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418519 | 0.87 | CACNA1B (0.59) | CACNA1BKCNH2L3MBTL1 | |
| SCHEMBL68318 | 0.87 | CACNA1B (0.59) | CACNA1BKCNH2L3MBTL1 | |
| SCHEMBL67295 | 0.85 | CACNA1B (0.51) | CACNA1BKCNH2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL66476 | 0.83 | CACNA1B (0.62) | CACNA1BKCNH2 | |
| SCHEMBL68399 | 0.83 | CACNA1B (0.59) | CACNA1BKCNH2 | |
| SCHEMBL2423819 | 0.81 | CACNA1B (0.68) | CACNA1B | |
| SCHEMBL67943 | 0.80 | CACNA1B (0.67) | CACNA1BKCNH2TEAD1 | |
| SCHEMBL2418520 | 0.79 | CACNA1B (0.63) | CACNA1BKCNH2 | |
| SCHEMBL68319 | 0.79 | CACNA1B (0.63) | CACNA1BKCNH2 | |
| SCHEMBL66791 | 0.78 | CACNA1B (0.53) | CACNA1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885KCNH2 24/4885L3MBTL1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.